Nordic Nanovector ASA: Financial calendar

OSLO, Norway, March 12, 2021 /PRNewswire/ --

FINANCIAL YEAR 2020

• 22.03.2021 - Extraordinary General Meeting
• 26.03.2021 - Annual Report

FINANCIAL YEAR 2021

• 28.04.2021 - Annual General Meeting
• 26.05.2021 - Quarterly Report - Q1
• 27.08.2021 - Half-yearly Report
• 18.11.2021 - Quarterly Report - Q3

For further information, please contact:                            

IR enquiries

Malene Brondberg, CFOCell: +44 7561 431 762Email: [email protected]

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)Tel: +44 203 926 8535Email: [email protected]

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--financial-calendar,c3305287

View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-financial-calendar-301246301.html

SOURCE Nordic Nanovector